Vir Biotechnology signs up to $1.875B Gilead deal for three T-cell engager cancer candidates

Vir Biotechnology announced a collaboration and license agreement with Gilead to discover and engineer three PRO-XTEN dual-masked T-cell engager development candidates targeting selected solid tumor-associated antigens. Gilead will pay $65M cash upfront and buy 1,765,486 shares at $14.16 each for $25M, plus up to $1.785B in milestones and royalties, for a total deal value of up to $1.875B.

Detected & updated continuously · Source: Nebula